Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration.

Authors

Ibrahim Mohammed Hepishy, Mo'men Salem, Ahmed El-Morsy, Khaled El-Adl, Naglaa M Ahmed

Published in

Bioorganic chemistry. Volume 181. Pages 110299. Jul 26, 2026. Epub Jul 26, 2026.

Abstract

The development of the C797S resistance mutation to third-generation tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer is a key therapeutic barrier, and this renders standard orthosteric site competitive inhibitors futile. Allosteric inhibitors of EGFR have emerged as a promising strategy for overcoming this resistance mechanism due to a structurally distinct binding site approximately 15-20 Å from the C797S mutation that confers potency independent of the status of cysteine-797. This comprehensive review summarizes the last decade of allosteric EGFR inhibitor medicinal chemistry, including 185 compounds across eight scaffold classes representing the entire reported landscape of efforts toward targeting EGFR with small molecules allosterically. The aminothiazole scaffold dominates the field with 57 compounds, followed by 4-anilinoquinazoline with 39 compounds; the focus of the field is concentrated on these privileged scaffolds. Five universal design principles governing allosteric potency have been identified through structure-activity relationship analysis: the formation of a hydrogen bond network, complementarity to a hydrophobic pocket, bivalent binding architecture based on a dual heterocycle, precise linker geometry, and core heterocycle identity. These principles account for the spectacular potency achievements that include 11 compounds reaching ultra-nanomolar potency (IC₅₀ < 1 nM) and 54 compounds attaining single-digit nanomolar activity. The aminothiazole-isoindolinone hybrid attained the most potent compound 4 with 0.10 nM, which is 20-fold, improved from the foundational EAI045 compound. The maturity of the field peaked in 2022 in optimization efforts, with 85 compounds reported. This review establishes that allosteric EGFR inhibition represents a clinically viable strategy for addressing osimertinib resistance, with lead candidates ready for clinical translation.

PMID:
42526135
Bibliographic data and abstract were imported from PubMed on 30 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.